Abstract: A hydration vest (1) having a vest plate (2) and a fluid container (3) removably attached thereto. The fluid container has a drinking tube (4) extending from a bottom of the fluid container (3) a sufficient length to reach over a wearer's shoulder into the mouth the wearer. The fluid container (3) encompasses a reservoir (10) having a centrally-located vertical bulkhead (12) extending from a top to proximate a bottom of the reservoir (10) in the fluid container (3). The hydration vest (1) is removably attachable around a torso of a person by a pair of shoulder straps (5) and a pair of waist straps (6).

Abstract: In certain embodiments, a computer-implemented method includes accessing a request to instantiate a virtual machine from a user, accessing virtual machine lifetime data, and determining, based at least in part on the virtual machine lifetime data, a probable lifetime for the virtual machine. The virtual machine lifetime data includes actual lifetime data for a prior virtual machine that was previously instantiated. The actual lifetime data indicates an amount of time that the prior virtual machine was operational.

Abstract: An excavation bucket assembly (10) is mounted to a tractor. A soil gathering trenching blade (48) is supported by an upwardly extending rear wall (18) and is movable down through a soil receiving opening (32) to scoop soil from beneath the ground wall (16) of the bucket, with the opening (32) being placed rearwardly of the front edge (30) of the ground wall, providing adequate space in the soil collection chamber (28) for receiving the excavated soil.

Abstract: Methods of detecting and treating rapidly growing exogenous cells, such as Protista, or parasites, that preferentially accumulate a photoactivatable porphyrin in which 5-aminolevulinic acid or precursor thereof is administered to the patient, or contacted to the exogenous cells, in an amount sufficient to induce synthesis fluorescence and/or photosensitizing concentrations of a protoporphyrin IX in the exogenous cells, followed by exposure of the exogenous cells to light of photoactivating wavelengths.

Abstract: An excavation bucket assembly (10) is mounted to a tractor. A soil gathering trenching blade (48) is supported by an upwardly extending rear wall (18) and is movable down through a soil receiving opening (32) to scoop soil from beneath the ground wall (16) of the bucket, with the opening (32) being placed rearwardly of the front edge (30) of the ground wall, providing adequate space in the soil collection chamber (28) for receiving the excavated soil.

Abstract: Methods of detecting and treating rapidly growing exogenous cells, such as Protista, or parasites, that preferentially accumulate a photoactivatable porphyrin in which 5-aminolevulinic acid or precursor thereof is administered to the patient, or contacted to the exogenous cells, in an amount sufficient to induce synthesis fluorescence and/or photosensitizing concentrations of a protoporphyrin IX in the exogenous cells, followed by exposure of the exogenous cells to light of photoactivating wavelengths.

Abstract: Methods of detecting and treating rapidly growing exogenous cells, such as Protista, or parasites, that preferentially accumulate a photoactivatable porphyrin in which 5-aminolevulinic acid or precursor thereof is administered to the patient, or contacted to the exogenous cells, in an amount sufficient to induce synthesis fluorescence and/or photosensitizing concentrations of a protoporphyrin IX in the exogenous cells, followed by exposure of the exogenous cells to light of photoactivating wavelengths.

Abstract: Methods of detecting and treating rapidly growing exogenous cells, such as Protista, or parasites, that preferentially accumulate a photoactivatable porphyrin in which 5-aminolevulinic acid or precursor thereof is administered to the patient, or contacted to the exogenous cells, in an amount sufficient to induce synthesis fluorescence and/or photosensitizing concentrations of a protoporphyrin IX in the exogenous cells, followed by exposure of the exogenous cells to light of photoactivating wavelengths.

Abstract: Methods of detecting and treating rapidly growing exogenous cells, such as Protista, or parasites, that preferentially accumulate a photoactivatable porphyrin in which 5-aminolevulinic acid or precursor thereof is administered to the patient, or contacted to the exogenous cells, in an amount sufficient to induce synthesis fluorescence and/or photosensitizing concentrations of a protoporphyrin IX in the exogenous cells, followed by exposure of the exogenous cells to light of photoactivating wavelengths.

Abstract: A computer implemented decision support tool serves as a solver to generate a best can do (BCD) match between existing assets and demands across multiple manufacturing facilities within boundaries established by manufacturing specifications and process flows and business policies to determine which demands can be met in what time frame by microelectronics (wafer to card) or related (for example disk drives) manufacturing and establishes a set of actions or guidelines for manufacturing to incorporate into their manufacturing execution system to insure the delivery commitments are met in a timely fashion. The BCD tool has six major components, a material resource planning explode or "backwards" component, an optional STARTS evaluator component, an optional due date for receipts evaluator, an optional capacity available versus needed component, an implode "forward" or feasible plan component, and a post processing algorithm.

Abstract: Methods of detecting and treating rapidly growing exogenous cells, such as Protista, or parasites, that preferentially accumulate a photoactivatable porphyrin in which 5-aminolevulinic acid or precursor thereof is administered to the patient, or contacted to the exogenous cells, in an amount sufficient to induce synthesis fluorescence and/or photosensitizing concentrations of a protoporphyrin IX in the exogenous cells, followed by exposure of the exogenous cells to light of photoactivating wavelengths.

Abstract: A method of detecting and treating malignant and non-malignant tissue abnormalities and lesions of the skin; conjunctiva; respiratory, digestive and vaginal mucosa; endometrium and urothelium; and for ablating the endometrial tissue and treating body fluids, including blood containing suspended abnormal cells, and for treating cancers of the nervous system in which 5-aminolevulinic acid or precursor thereof is administered to the patient in an amount sufficient to induce synthesis fluorescence and/or photosensitizing concentrations of a protoporphyrin IX in the abnormal cells, followed by exposure of the abnormal cells to light of photoactivating wavelengths.

Abstract: A method of detecting and treating malignant and non-malignant tissue abnormalities and lesions of the skin; conjunctiva; respiratory, digestive and vaginal mucosa; endometrium and urothelium; and for ablating the endometrial tissue and treating body fluids containing suspended abnormal cells, and for treating cancers of the nervous system in which 5-aminolevulinic acid or precursor thereof is administered to the patient in an amount sufficient to induce synthesis fluorescence and/or photosensitizing concentrations of of protoporphyrin IX in the abnormal cells, followed by exposure of the abnormal cells to light of photoactivating wavelengths.

Abstract: A method of detecting and treating malignant and nonmalignant tissue abnormalities and lesions of the skin, conjunctives, respiratory, digestive and vaginal mucosa; endometrium and urothelium in which 5-aminolevulinic acid is administered to the patient in an amount sufficient to induce synthesis of protoporphyrin IX in the lesions, followed by exposure of the treated lesion to a photoactivating light in the range 350-640 nm.

Abstract: A method of detecting and treating malignant and non-malignant tissue abnormalities and lesions of the skin, conjunctives, respiratory, digestive and vaginal mucosa; endometrium and urothelium in which 5-aminolevulinic acid is administered to the patient in an amount sufficient to induce synthesis of protoporphyrin IX in the leisons, followed by exposure of the treated lesion to a photoactivating light in the range 350-640 nm.

Abstract: This disclosure relates to a vascular connector device which has features that permit the connector device to close a vascular duct and to subsequently permit the vascular duct to be re-opened, if desired. The vascular connector of this disclosure features a tubular shaped vascular connector having a guillotine type plunger arrangement or assembly which can be actuated for first closing and then re-opening the vascular duct, if desired.